ArticleBiomedical reports2025
Valproic acid exposure alters histone deacetylase mRNA expression profile in oral cancer and premalignant cell lines.
Article in Biomedical reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The common frequent precursors to head and neck squamous cell carcinoma (HNSCC) are oral dysplasias (ODs). Nonetheless, methods for prediction or prevention of the malignant transformation of OD are unreliable. Therefore, oral HNSCC is often diagnosed in the advanced stages of the disease. Abnormalities in histone acetylation in oral cancers include aberrant histone deacetylase (HDAC) expression. Therefore, HDAC inhibitors (HDACis) have potential in the treatment of HNSCC and chemoprevention for patients with high-risk OD. Valproic acid (VPA), is an anti-epileptic drug that shows HDACi activity, specifically targeting Class IIa HDACs, with efficacy against HNSCC cells; however, the molecular changes in response to VPA remain unclear. The present study aimed to determine how VPA exposure affects Class IIa HDAC mRNA expression in oral cancer cell lines (UM-SCC-10A, UM-SCC-11B, UM-SCC-12, UM-SCC-17A, HN5, PE/CA-PJ15, UM-SCC-1, BHY, PE/CA-PJ41 and UM-SCC-81B) and premalignant cells (D19, D20 and D35). Reverse transcription-quantitative PCR (RT-qPCR) revealed a trend of upregulation of HDAC4 and HDAC5, and downregulation of HDAC7 in all of the examined cells in response to 1 mM VPA exposure at different time points (6, 24 or 48 h). A total of three cell lines (precancerous D20 tongue immortal dysplastic cells, BHY oral squamous cell carcinoma cells and UM-SCC-10A laryngeal squamous cell carcinoma cells; ≥2-fold differences in HDAC expression following VPA treatment) were selected for further investigations using RT-qPCR to confirm the VPA-mediated alteration of HDAC mRNA expression. VPA-dependent epigenetic reprogramming resulted in transcriptional alterations of Class IIa HDACs in HNSCC and premalignant cells. The clinical relevance of these alterations in the pathogenesis of HNSCC must be further determined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.